OSI-027 is a next generation mammalian target of rapamycin (mTOR) kinase inhibitor that inhibits the kinase activity associated with both the TORC1 and TORC2 complexes of mTOR. This dual TORC1 and TORC2 activity differentiates our compound from rapamycin and the various related analogs, or rapalogs, that are currently in clinical development in that these molecules only inhibit TORC1 activity. In addition, researchers at OSI have found that the combination of an EGFR inhibitor, like Tarceva^®, with an inhibitor of mTOR is synergistic in certain tumor cell lines. The Company expects to file an IND for OSI-027 before the end of the fourth quarter of 2007.